Table 3.
Multiple logistic regression estimated OR (95 % CI) for non-alcoholic fatty liver disease (NAFLD) by Healthy Lifestyle Score (HLS) in all subjects, men and women
| Exposures | n (total/cases) | Model 1* | Model 2† | ||||
|---|---|---|---|---|---|---|---|
| OR | 95 % CI | P-value | OR | 95 % CI | P-value | ||
| All subjects | 2981/1515 | ||||||
| HLS 0–1 | 238/142 | Ref. | Ref. | ||||
| HLS 2 | 718/409 | 0·86 | 0·64, 1·16 | 0·327 | 0·85 | 0·63, 1·15 | 0·281 |
| HLS 3 | 984/505 | 0·68 | 0·51, 0·91 | 0·010 | 0·68 | 0·51, 0·91 | 0·010 |
| HLS 4 | 753/355 | 0·58 | 0·43, 0·79 | <0·001 | 0·58 | 0·43, 0·78 | <0·001 |
| HLS 5–6 | 288/104 | 0·37 | 0·26, 0·52 | <0·001 | 0·35 | 0·25, 0·51 | <0·001 |
| Men | 954/515 | ||||||
| HLS 0–1 | 36/18 | Ref. | Ref. | ||||
| HLS 2 | 235/140 | 1·45 | 0·72, 2·94 | 0·300 | 1·33 | 0·65, 2·75 | 0·440 |
| HLS 3 | 342/190 | 1·24 | 0·62, 2·47 | 0·543 | 1·21 | 0·59, 2·45 | 0.604 |
| HLS 4 | 235/122 | 1·07 | 0·53, 2·17 | 0·847 | 1·03 | 0·50, 2·13 | 0·936 |
| HLS 5–6 | 105/45 | 0·76 | 0·35, 1·62 | 0·472 | 0·69 | 0·32, 1·52 | 0·362 |
| Women | 2027/1000 | ||||||
| HLS 0–1 | 202/124 | Ref. | Ref. | ||||
| HLS 2 | 483/269 | 0·78 | 0·56, 1·10 | 0·155 | 0·74 | 0·48, 1·15 | 0·180 |
| HLS 3 | 642/315 | 0·60 | 0·44, 0·83 | 0·002 | 0·51 | 0·34, 0·77 | 0·001 |
| HLS 4 | 518/233 | 0·52 | 0·37, 0·72 | <0·001 | 0·44 | 0·28, 0·67 | <0·001 |
| HLS 5–6 | 182/59 | 0·32 | 0·21, 0·48 | <0·001 | 0·25 | 0·15, 0·41 | <0·001 |
Ref., Reference category.
*
Model 1: adjusted for age and sex (for all subjects only).
†
Model 2: further adjusted for marital status, education level, household income, history of using statins and daily energy intake. For women, menopausal age and oral oestrogen use were further adjusted.